CheckMyRecalls

Cipla USA, Inc. recalls Nilotinib Capsules

Published
11 Mar 2026
Units affected
2 products
Agency
FDA
Country
United States

The hazard

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Classification: Class III — this product is unlikely to cause health problems but breaks FDA rules (for example labeling).

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each) NDC 69097-031-74; Inner carton: 28 capsules (4 blisters of 7 capsules) NDC 69097-031-56; Foil blister: NDC 69097-031-17

Nilotinib Capsules, 200 mg per capsule, packaged in cartons, Rx only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each), NDC 69097-032-74; Inner carton: 28 capsules (4 blisters of 7 capsules), NDC 69097-032-56; Foil blister: NDC 69097-032-17

Brand / company
Cipla USA, Inc.
Codes / lots
Lot #: 5GJ0220, 5GJ0221, 5GJ0222, Exp 04/30/2027 | Lot #: 5GJ0223, Exp 04/30/2027
Distribution
U.S.A. Nationwide
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 11 Mar 2026. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.